In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A humanized monoclonal antibody that specifically binds to a Shiga toxin 1 (Stx1) or Shiga toxin 2 (Stx2) antigen ~~Shiga~~ toxin protein, comprising a constant region and a variable region, wherein said constant region ~~contains at least part of~~ comprises a human immunoglobulin constant region and said variable region ~~contains at least part of an~~ comprises the immunoglobulin heavy chain and light chain variable ~~region~~ regions as shown in Figure 3 (SEQ ID ~~NO:~~ NOs: 19 and 21) or the immunoglobulin heavy chain and light chain variable regions as shown in Figure 6 (SEQ ID ~~NO:~~ NOs: 42 and 44), wherein the antibody specifically ~~reacts with~~ binds to Stxl or Stx2 antigen.

2-16. (Cancelled)

17. (Previously presented) The humanized monoclonal antibody of claim 1, wherein said human immunoglobulin constant region is selected from the group consisting of IgG, IgA, and IgM.

18. (Previously presented) The humanized monoclonal antibody of claim 17, wherein said human immunoglobulin constant region is IgG.

19. (Currently amended) A humanized monoclonal antibody which specifically binds to Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:

said constant region is ~~IgG1-kappa,~~ a human immunoglobulin constant region, and

said variable region ~~contains at least a part of the sequence as set forth in SEQ ID NO: 42 and SEQ ID NO: 44~~ comprises the murine 11E10 (ATCC Accession No. CRL 1987) variable region.

20-22. (Cancelled)

23. (Previously presented) A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

24-28. (Cancelled)

29. (Previously presented) A pharmaceutical composition comprising the

antibody of claim 19 and a pharmaceutically acceptable carrier or diluent.

30-33. (Cancelled)

34. (Currently amended) The humanized monoclonal antibody of claim ~~32~~ 19, wherein the human constant region is selected from the group consisting of IgG, IgA and IgM.

35. (Currently amended) The humanized monoclonal antibody of claim ~~32~~ 34, wherein the human constant region is IgG.

36. (Currently amended) The humanized monoclonal antibody of claim ~~32~~ 35, wherein the human constant region is IgGl-kappa.

37. (Currently amended) The humanized monoclonal antibody of claim ~~32~~ 1, wherein the antibody specifically binds to Stx1 and the variable region comprises the amino acid sequence of SEQ ID ~~NO:~~ NOs: 19 and 21 ~~42~~.

38. (Currently amended) The humanized monoclonal antibody of claim ~~32~~ 1, wherein the antibody specifically binds to Stx2 and the variable region comprises the

amino acid sequence of SEQ ID ~~NO:~~ NOs: 42 and 44.

39-43. (Cancelled)

44. (Currently amended) A pharmaceutical composition ~~The pharmaceutical composition of claim 23, said composition~~ comprising a first and second antibody of claim 1 and a pharmaceutically acceptable carrier or diluent, wherein the first antibody of claim 1 specifically ~~reacts with~~ binds to Stx2 antigen and comprises the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs: 42 and 44 and the second antibody of claim 1 specifically ~~reacts with~~ binds to Stx1 antigen and comprises the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs: 19 and 21.

45-46. (Cancelled)

47. (Currently amended) The pharmaceutical composition of claim 29, further comprising a humanized monoclonal antibody that specifically binds to Stx1 antigen, wherein said humanized monoclonal antibody that specifically binds to Stx1 antigen comprises the murine 13C4 (ATCC Accession No. CRL 1794) variable region and a human immunoglobulin constant region.

48-53. (Cancelled)

54. (Currently amended) The pharmaceutical composition of claim ~~53~~ 47, wherein said antibody of claim ~~32~~ 19 comprises an IgG1 kappa human immunoglobulin constant region.

55. (Currently amended) The pharmaceutical composition of claim ~~53~~ 47, wherein said humanized antibody that specifically binds to Stx1 antigen comprises an IgG1 kappa human immunoglobulin constant region ~~at least part of SEQ ID NO: 19 or SEQ ID NO: 21~~.

56. (New) A humanized monoclonal antibody that specifically binds to Shiga toxin type 1 and Shiga toxin type 1 variants, comprising a constant region and a variable region, wherein:

said constant region is a human immunoglobulin constant region, and

said variable region comprises the murine 13C4 (ATCC Accession No. CRL 1794) variable region.

57. (New) A pharmaceutical composition comprising the antibody of claim 56

and a pharmaceutically acceptable carrier or diluent.

58. (New) The humanized monoclonal antibody of claim 56, wherein the human constant region is selected from the group consisting of IgG, IgA and IgM.

59. (New) The humanized monoclonal antibody of claim 58, wherein the human constant region is IgG.

60. (New) The humanized monoclonal antibody of claim 59, wherein the human constant region is IgGl-kappa.

61. (New) The pharmaceutical composition of claim 57, further comprising a humanized monoclonal antibody that specifically binds to Stx2 antigen, wherein said humanized monoclonal antibody that specifically binds to Stx2 antigen comprises a human immunoglobulin constant region and a variable region, wherein said variable region comprises the murine 11E10 (ATCC Accession No. CRL 1987) variable region.

62. (New) The pharmaceutical composition of claim 61, wherein said humanized monoclonal antibody that specifically binds to Shiga toxin type 1 and Shiga toxin type 1 variants comprises an IgG1 kappa human immunoglobulin constant region.

63. (New) The pharmaceutical composition of claim 61, wherein said humanized antibody that specifically binds to Stx2 antigen comprises an IgG1 kappa human immunoglobulin constant region.